Hyperactivity of corticotropin-releasing factor (CRF) neurons in the paraventricular nucleus (PVN) of the hypothalamus is a prominent feature in depression and may be important in the etiology of this disease. The activity of the CRF neurons in the stress response is modulated by a number of factors that stimulate or inhibit CRF expression, including (1) corticosteroid receptors and their chaperones, heat shock proteins 70 and 90, (2) sex hormone receptors, (3) CRF receptors 1 (CRFR1) and 2, (4) cytokines interleukin 1-b and tumor necrosis factor-a, (5) neuropeptides and receptors, vasopressin (AVP), AVP receptor 1a (AVPR1A) and oxytocin and (6) transcription factor cAMP-response element-binding protein. We hypothesized that, in depression, the transcript levels of those genes that are involved in the activation of the hypothalamo-pituitary-adrenal (HPA) axis are upregulated, whereas the transcript levels of the genes involved in the inhibition of the HPA axis are downregulated. We performed laser microdissection and real-time PCR in the PVN and as a control in the supraoptic nucleus. Snap-frozen post-mortem hypothalami of seven depressed and seven matched controls were used. We found significantly increased CRF mRNA levels in the PVN of the depressed patients. This was accompanied by a significantly increased expression of four genes that are involved in the activation of CRF neurons, that is, CRFR1, estrogen receptor-a, AVPR1A and mineralocorticoid receptor, while the expression of the androgen receptor mRNA involved in the inhibition of CRF neurons was decreased significantly. These findings raise the possibility that a disturbed balance in the production of receptors may contribute to the activation of the HPA axis in depression.
Introduction
The hypothalamo-pituitary-adrenal (HPA) axis is considered to be the 'final common pathway' for a major part of the depressive symptomatology. Stressful life events and genetic-and epigenetic-risk factors for depression have been linked to increased HPAaxis activity in adulthood. 1 When patients or animal models for depression are treated either with antidepressants, or with electroconvulsive therapy, or when patients show spontaneous remission, the HPAaxis function returns to normal. 2 Moreover, studies in high-risk probands of patients with major depression (MD) have shown that abnormalities in HPA-axis function already exist prior to the onset of the clinical symptoms, suggesting that such abnormalities can, in fact, precede depressive episodes. 3 The hyperactivity of the corticotropin-releasing factor (CRF) neurons is important in the neurobiology of depression as it appears from (1) an increased amount of CRF mRNA in the paraventricular nucleus (PVN) as determined by in situ hybridization in depression, (2) a fourfold increase in the number of CRF-expressing neurons in the PVN and (3) the increased number of CRF neurons co-expressing vasopressin (AVP). 4, 5 An important argument for a causal role for central effects of CRF in depression is that similar symptoms, such as decreased food intake, decreased sexual activity, disturbed sleep and motor behavior, and anxiety can all be induced in experimental animals by intracerebroventricular injection of CRF. 6 An additional argument for the direct involvement of CRF in the symptomatology of depression is the recently found increased susceptibility to MD in case of a single-nucleotide polymorphisms in the CRF receptor 1 (CRFR1) gene. 7, 8 Antidepressants attenuate the synthesis of CRF by upregulation of corticosteroid receptor expression 1 that causes a decrease of the cerebrospinal fluid (CSF) levels of CRF. 9 A transgenic mouse model with an overproduction of CRF showed increased anxiogenic behavior, a symptom that is usually related with MD, and that could be counteracted by injection of a CRF antagonist. 10 Lastly, CRF-receptor antagonists may be effective in the treatment of depression. 11, 12 Together, these arguments have led to the CRF hypothesis of depression: hyperactivity of CRF neurons, and in particular those driving the HPA axis, induces symptoms of depression.
The CRF neurons of the activated HPA axis do not only stimulate cortisol production by the adrenal gland but also project centrally. Both this centrally released CRF and these increased levels of cortisol contribute to the signs and symptoms of depression (for review see Bao et al. 1 ). In addition, there is interaction of the HPA axis, both by centrally projecting CRF and via cortisol, with the monoaminergic systems and with the prefrontal cortex. [13] [14] [15] Alterations in these systems also contribute to the mood changes.
The activity of CRF neurons is modulated by a large number of factors that can be produced in the PVN and may also be involved in the pathogenesis of depression, that is, (1) a change in corticosteroid feedback on the HPA axis involving the glucocorticoid receptor (GR) (that is, GRa) and the mineralocorticoid receptor (MR). MR and GR can form hetero-and homodimers that differ in their activity of gene regulation. A change in the balance of MR/GR ratio in depressed patients may contribute to the change in transcription rate of CRF [16] [17] [18] [19] [20] ; (2) the CRF receptors, that is, CRFR1 that stimulates CRF production 21, 22 and CRFR2 that opposes this action 23 ; (3) alterations in vasopressinergic systems that potentiate effects of CRF 24 and the AVP receptor 1a (AVPR1A) that is involved in anxiety/ depressionrelated behavior 25 ; oxytocin (OXT) that attenuates the stress response was found to be increased in the PVN only in melancholic depression 26 ; (4) cAMP-response element-binding protein (CREB) that stimulates CRF expression as a transcription factor 27 ; (5) sex hormones, involving estrogen-receptors (ESR) 1 and 2 and androgen-receptor (AR), stimulating and inhibiting CRF gene expression, respectively 28, 29 ; (6) the powerful CRF-stimulating proinflammatory cytokines such as interleukin 1-b (IL1b) that is produced by glial cells and PVN neurons, 30 and tumor necrosis factor-a (TNFa), a circulating state marker for depression 31 that is also produced by glial cells 32 ;
(7) the heat shock proteins (HSP) 70 and 90 that are determinants of glucocorticoid resistance. 33 We hypothesized that, in depression, the transcript levels of those genes that are involved in the activation of the HPA axis (CRF, CRFR1, MR, AVP, AVPR1A, CREB, ESR1, ESR2, IL1b, TNFa, HSP70 and 90) are upregulated whereas the transcript levels of the genes involved in the inhibition of the HPA axis (GRa, CRFR2, AR, OXT) are downregulated.
For the first time, we performed laser microdissection (LMD) and real-time quantitative PCR (qPCR) on the isolated PVN and supraoptic nucleus (SON) from snap-frozen post-mortem hypothalami of seven depressed and seven matched controls to determine changes at the transcript level of these feedback and input factors in depression. Subsequently, we determined the transcript levels of peptides of the stress axis, that is, CRF, AVP and OXT, and transcription factors that are possibly involved in the hyperactivity of the CRF neurons in depression, and thus in the pathogenesis of this disease. The hypothesis we wanted to test was whether there was a receptor imbalance such as the one proposed between MR and GR 16 in the PVN in the depressed patients, and if that was the case, whether such an imbalance also exists for other related receptors. The transcripts of these targets were also determined in the SON, as a control area, since this nucleus hardly produces CRF, and AVP expression was only activated in the SON in the melancholic type of depression, 26 while this type of depression was only present in one of the seven depressed patients in the present study.
Materials and methods

Subjects
The hypothalami were obtained by autopsy from 14 subjects of which 7 were patients clinically diagnosed with depression, either in the context of a MD or of a bipolar disorder (BD), and 7 served as controls matched for sex, age, post-mortem delay, season and clock time of death, and brain weight. The depression and control groups were matched for sex, age (z = À0.192, P = 0.848), season and clock time of death (w 2 = 1.902, P = 0.386; w 2 = 2.406, P = 0.300, respectively), brain weight (z = À0.704, P = 0.482), postmortem delay (z = À0.576, P = 0.565) and for pH of the CSF (z = À1.146, P = 0.252) that is a measure of agonal state (for clinicopathological information see Table 1 ). The frozen brain material was obtained from the Netherlands Brain Bank, following permission from the patient or the next of kin for a brain autopsy and for the use of the brain material and clinical information for research purposes. The patients suffering from depression were diagnosed during their life and the diagnosis was checked by a certified psychiatrist (Dr G Meynen) retrospectively using the medical record, who paid special attention to the presence of melancholic features according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria (American Psychiatric Association). Five patients fulfilled the criteria for MD and two patients fulfilled the criteria for BD. For detailed information, also on the relevant medication in the past and in the last month before death ( Table 1 ). The medical records did not reveal any alcohol or other drug abuse among subjects of either group. The absence or presence of neuropathological changes, both in the patients with mood disorders and in the controls, was confirmed by systematic neuropathological investigation. 35 The results are set down in Table 1 .
Human brain material
Laser microdissection. The freshly frozen hypothalami were serially sectioned at À15 1C on a cryostat (Leica CM 1850 UV) at a thickness of 20 mm from rostral to caudal throughout the PVN and the SON. The PVN and the SON were dissected at the right side of the hypothalamus. The beginning and the end of the PVN and the SON were defined by thionin staining every 10th section from rostral to caudal throughout the hypothalamus. The tissue sections were thaw mounted on a slide coated with a plain film (Birkelbach Film, Germany). In total, there were 126-328 serial sections obtained from the most rostral to the most caudal part of the SON and PVN (the variation of the section numbers due to the orientation of the frozen block). We took 3 out of the 9 unstained sections of every 10 sections (of which one was stained with thionin). In this way, a total of 66 ± 3 (mean ± s.e.m.) sections of PVN in depression and 64 ± 8 in controls (P = 0.304 in Mann-Whitney U-test); 60±3 sections of SON in depression and 51±4 in controls (P = 0.14 in Mann-Whitney U-test) were sampled for LMD in each patient. The frozen sections were stored under vacuum at room temperature with silica gel for dehydration for two nights, and the PVN and SON were dissected from the sections by a PALM MicroLaser System (Bernried, Germany) ( Figure  1 ) and collected by hand, using a fine needle. 36 RNA isolation. For RNA extraction from the LMD tissue, we used an adapted protocol of the RNeasy protocol (Qiagen, Hilden, Germany). Trizol (1 ml) (Invitrogen Life Technologies, Carlsbad, CA, USA) was added to the vial containing all the dissected material of the PVN or SON of one patient. After spinning down at 12 000 g for 10 min at 4 1C, the supernatant was transferred into another tube; 200 ml chloroform was added to the supernatant, vortexed for 15 sec and centrifuged for 15 min at 12 000 g at 4 1C. The upper aqueous phase was transferred into a clean vial and an equal volume of freshly prepared 70% ethanol was added, after which the sample was loaded onto an RNeasy column. RNA was extracted according to RNeasy (Qiagen) manufacturer's protocol. RNA quantity was measured on a NanoDrop 1000 spectrophotometer (NanoDrop Technologies, Rockland, DE, USA) and the quality was determined by a 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA, USA). RNA integrity number (RIN) was used to assess the RNA quality (scale 1-10, with 1 being the lowest and 10 being the highest RNA quality).
cDNA synthesis. For each sample, an equal quantity of RNA (300 ng) was used for the synthesis of cDNA, mixed with 4.1 ml mixture of oligo dT (100 mg ml À1 ) and 10 Â hexanucleotide (Roche, Basel, Switzerland) (40:1 for the oligodT and hexanucleotide mixture), heated to 80 1C for 10 min, after which the tubes were quickly transferred to ice. Then 1 ml reverse transcriptase Superscript II RT (Invitrogen Life Technologies) was added together with a mixture of 5 ml 5Â first-strand buffer, 2.5 ml 100 mM dithiothreitol, 1.5 ml 10 mM dNTPs and 0.5 ml RNase inhibitor. The synthesis reaction was allowed to proceed for 1 h at 42 1C, after which cDNA was stored at À20 1C or used immediately.
Primer design. The mRNA sequences for all of the genes were downloaded from the NCBI at http:// www.ncbi.nlm.nih.gov. The primers were designed by Primer Premier (version 5.0) to amplify specific amplicons. Sequences and size of the primer pairs are shown in Table 2 . Most primer pairs were designed to span the 3 0 -most intron to avoid amplification of DNA templates that may be present in trace amounts in the RNA samples. qPCR assays using intron-specific primer pairs revealed high C t values of X37, showing that the amounts of DNA were negligible. Since none of the samples used in our study showed an amplification of DNA-specific sequences, it may be concluded that the qPCR data also obtained by the non-intron spanning primers for which intronspanning primers were not optimal or not possible (that is, for CRF, AVP, OXT, HSP70) yields information on transcript levels without confounding coamplification of genomic DNA.
Quantitative PCR. The qPCR reaction contained 10 ml 2Â SYBR Green Mastermix (Applied Biosystems, Foster City, CA, USA), 1 ml of each primer pair (1 mM) and 5 ml (equivalent to 2 ng ml À1 total RNA) of template cDNA in a 20 ml reaction volume. The PCR was performed in a GeneAmp 7300 thermocycler PCR program: 10 min at 95 1C, followed by 40 cycles of 15 s at 95 1C and 1 min at 60 1C). The specificity of the amplification was checked by melting curve analysis and electrophoresis of the products on an 8% polyacrylamide gel. Sterile water, RNA samples without addition of reverse transcriptase in the cDNA synthesis and DNA samples were used as a control. The linearity of each qPCR assay was tested by preparing a series of dilutions of the same stock cDNA in multiple plates. A normalization strategy was used for the gene quantification. The relative absolute amount of target genes were calculated by 10 10 Â E Àct (E = 10
). 37 Normalization strategy. To remove sampling-related differences (RNA quality and RNA quantity), a normalization strategy based upon the geNorm approach was followed. 38 The geNorm analysis revealed that the transcript level of all eight reference genes that were determined in the PVN and the SON could be included into the calculation of the normalization factor. The normalization factor was the geometric mean of the following genes: glyceraldehydes-3-phosphate dehydrogenase (GAPDH), actin-b (ACTb), 18S ribosomal RNA (RN18S, hydroxymethylbilane synthase (HMBS), hypoxanthine phosphoribosyltransferase 1 (HPRT1), ubiquitin C (UBC), tubulin-a (TUBa), tubulin-b4 (TUBb4). The absolute amount of transcript thus determined was then divided by the normalization factor to obtain the normalized values.
Considerations in relation to the reference genes. There are a number of reports indicating that the classic reference genes may be regulated under certain conditions and may therefore be unsuitable for normalization purposes. 39, 40 In fact, every experimental situation has its own ideal normalization method. 41 Some reports indeed indicate that the use of the internal standards comprising single reference genes or ribosomal RNA is inappropriate, 42 such as RN18S. 43 In the present study, we therefore chose to combine reference genes according to the geNorm program, using the pair-wise comparison. We used the geometric mean as the normalization factor. 38 
Statistic analysis
Statistic analysis was conducted with SPSS (version 11.5, SPSS Incorporation). The differences between the groups were statistically evaluated by the nonparametric Mann-Whitney U-test since the data were not distributed normally. We compared the data of depression versus control in PVN and SON separately. Differences in clock time of death and month of death (circular parameters) between control and patients with mood disorders were tested with the Mardia-Watson-Wheeler test. 44 The association between the target genes was examined by the Spearman's correlation coefficient. The tests of association were corrected according to Bonferroni. Whether the 16 tested genes in the PVN changed their expression in depression into the direction predicted by our hypothesis was tested by the Sign test of proportions. Tests were two tailed. Values of P < 0.05 were considered to be significant.
Results
RNA quality
Because the overall RNA quality is a major factor in studies on gene expression, we determined whether the RIN value was influenced by confounding factors. The mean RIN of the LMD samples was 7.2±0.6 in the PVN and 6.6 ± 0.7 in the SON. However, we found no significant difference in RIN values between the depression group and the control group (z = À1.529, P = 0.126).
Gene expression in the PVN in depression versus controls Transcript levels of CRF, CRFR1, MR and ESR1 were found to be significantly higher in the PVN in the GTGTGAGATGTGCTTTCTGGTTT  HSP90  CGCTCCTGTCTTCTGGCTTC  NM_005348  117  TGGTATCATCAGCAGTAGGGTCA  HSP70  CCATCATCAGCGGACTGTACC  NM_005345  87  CTGACCCAGACCCTCCCTT  MR  AAGTCGTGAAGTGGGCAAAG  NM_000901  83  CCAAGAATACTGGATTAGGGT  OXT  GCTGAAACTTGATGGCTCCG  NM_000915  67  TTCTGGGGTGGCTATGGG  TNFa  GGCGTGGAGCTGAGAGATA  NM_000594  88  CAGCCTTGGCCCTTGAAGA  IL1b  CCGACCACCACTACAGCAA  NM_000576  86  GGCAGGGAACCAGCATCT  ACTb  CCCAGCCATGTACGTTGCTA  NM_001101  65  TCACCGGAGTCCATCACGAT  GAPDH  CAAATTCCATGGCACCGTC  NM_002046  62  TCTCGCTCCTGGAAGATGGT  HPRT1  GGACAGGACTGAACGTCTTGC  NM_000194  88  ATAGCCCCCCTTGAGCACAC  TUBa  CTTTGAGCCAGCCAACCAGA  NM_006082  72  GTACAACAGGCAGCAAGCCAT  UBC  GCTGCTCATAAGACTCGGCC  NM_021009  70  GTCACCCAAGTCCCGTCCTA  HMBS  GATCCCGAGACTCTGCTTCG  NM_001024382  70  ACACTGCAGCCTCCTTCCAG  TUBb4  GGGCCAAGTTTTGGGAGGT  NM_006087  71  CACTGTCCCCATGGTATGTGC  RN18S  TCGAGGCCCTGTAATTGGAA  M10098  60  CCCTCCAATGGATCCTCGTT Abbreviations: ACTb, actin-b; AR, androgen receptor; AVP, vasopressin; AVPR1A, AVP receptor 1a; CREB, cAMP-response element-binding protein; CRF, corticotropin-releasing factor; CRFR, CRF receptor; ESR, estrogen receptor; GAPDH, glyceraldehydes-3-phosphate dehydrogenase; GR, glucocorticoid receptor; HMBS, hydroxymethylbilane synthase; HPRT1, hypoxanthine phosphoribosyltransferase 1; HSP, heat shock protein; IL1b, interleukin 1-b ; MR, mineralocorticoid receptor; OXT, oxytocin; RN18S, 18S ribosomal RNA; TNFa, tumor necrosis factor-a; TUBa, tubulin-a; UBC, ubiquitin C. depression group while AR was decreased compared to the controls (Table 3 ). The median of the total amount of CRF mRNA in the PVN was 1.9 times higher than that of the controls (z = À1.981, P = 0.048, Figure 2a ). The median amount of CRFR1 mRNA in the PVN was B2.5 times higher than that in controls (z = À1.981, P = 0.048, Figure 2b ). In depression, the sex hormone receptor expression levels in the PVN changed significantly. The amount of AR mRNA in the PVN was decreased by B2.7-fold in the depressed patients as compared to the controls (z = À1.981, P = 0.048, Figure 2f ), while the amount of ESR1 mRNA was B1.7 times higher than that of the controls (z = À2.492, P = 0.013, Figure 2d ). The MR mRNA levels of the depressed patients were B2.2 times higher than those of the controls (z = À2.747, P = 0.006, Figure 2c ) and the AVP mRNA levels were B1.9 times higher in the depressed patients than in the controls, a trend that did not reach significance (z = À1.597, P = 0.11). The AVPR1A level was B2 times higher in the PVN of depressed patients than in the controls (z = À1.981, P = 0.048, Figure 2e ).
We hypothesized that in depression the transcript levels of those genes that are involved in the activation of the HPA axis (CRF, CRFR1, MR, AVP, AVPR1A, CREB, ESR1, ESR2, IL1b, TNFa, HSP70 and 90) are upregulated, whereas the transcript levels of the genes involved in the inhibition of the HPA axis (GRa, CRFR2, AR, OXT,) are downregulated. From the 16 tested genes in the PVN, 13 changed their expression in depression into the direction predicted by our hypothesis (Table 3) , which the Sign test for proportions deemed significant (a < 0.05).
There were interesting correlations present between the expression levels of sex hormone receptors in the PVN in the depressed patients but not in the controls. ESR1 mRNA was positively correlated with estrogen receptor-b (ESR2) mRNA in the PVN, both in the depressed patients and in the controls (Figure 3a) (r = 0.893, P = 0.007; r = 0.821, P = 0.023, respectively). A significant correlation was found between AR-and ESR1-mRNA (r = 0.857, P = 0.014) and AR-and ESR2-mRNA (r = 0.857, P = 0.014) (Figure 3b ) in the PVN but only in the depressed patients.
Gene expression in the SON in depression and controls
No significant difference of these target genes was found in the SON between the depressed patients and the controls as far as these target genes are concerned.
Gene expression in the PVN and the SON of depressed patients and controls
The transcript levels of CRF, OXT, GRa, AR and ESR1 were found to be significantly higher in the PVN than in the SON both in the depressed patients and in the controls (Table 4) , whereas the MR, ESR2 and CRFR1 were significantly more expressed in the PVN in the depressed patients than in the controls. There was no significant change of AVP mRNA in SON and PVN of depressed patients. A similar level of expression for the PVN and the SON was found for CREB, TNFa, The values represent the total amount of gene expression in the PVN. *P < 0.05, **P < 0.01.
IL1b, CRFR2, HSP70 and 90. GR subtype-b (GRb) mRNA was not detected by real-time qPCR, probably because of its low abundance (Table 4) .
Discussion
The present study shows that in depression, the increase in CRF expression was accompanied by a significant increased expression of four genes that are involved in activation of CRF neurons, that is, CRFR1, ESR1, MR and AVPR1A, while the expression of the AR that is involved in the inhibition of CRF neurons was decreased significantly. The direction in which 13 out of the 16 genes changed their expression level was significant and confirmed our hypothesis. The data were obtained in the PVN and SON of depressed patients and controls, using for the first-time LMD of the SON and PVN tissue followed by real-time qPCR in these patients. The results indicate that depression is accompanied by an imbalance in the expression of genes regulating the HPA axis. Figure 2 Transcript levels of corticotropin-releasing factor (CRF) (a), CRF receptors 1 (CRFR1) (b), mineralocorticoid receptor (MR) (c), estrogen-receptor (ESR) 1 (d) and vasopressin receptor 1a (AVPR1A) (e) were found to be significantly higher in the paraventricular nucleus (PVN) of the depression group while androgen receptor (AR) (f) was significantly decreased compared to the controls. Dots represent the total expression levels in the PVN and supraoptic nucleus (SON) of individual depressed subjects (n = 7) and controls (n = 7). The numbers 1-7 beside the dots represent the patients correlated to D1-D7, respectively, in Table 1 . C1-C7 represents the controls. Numbers 3 and 6 represent the two bipolar disorder (BD) patients. The horizontal line indicates the median value. The asterisk demonstrates a significant difference in the PVN in depression versus controls. *P < 0.05; **P < 0.01.
CRF neurons and CRFR1 and CRFR2 imbalance
The CRF hypothesis of depression is supported in our study by the increased total amount of CRF mRNA in the PVN of depressed patients, now for the first time determined by real-time PCR. This confirms our earlier studies in depressed patients with other techniques, showing an increase in the number of CRF-immunopositive neurons in depression 4, 28 and elevated levels of CRF mRNA as determined by in situ hybridization. 5 So far, only one related study 45 on brain tissue in suicide victims has been carried out in which no significant increase of CRF mRNA in the PVN was found. However, in the study, the concentration of CRF was measured in a PVN punch and not the total amount of CRF mRNA in the PVN, as we did in the present study.
Our new finding of an enhanced amount of CRFR1 mRNA in the PVN in depressed patients supports the CRF hypothesis of depression. No information on this receptor has been available for the human brain until now. Although observations in human post-mortem material can only reveal correlations and cannot distinguish cause and effect, our findings are fully supported by the enhanced CRF expression in the PVN in various types of stress in rodents that mediates CRF-induced ACTH secretion, anxiety and anorectic effects. CRFR1 expression occurs widely in the central nervous system indicating a large number of sites of CRF action. The expression of CRFR1 is low within the PVN but substantially and selectively increases after stress. 46 It is surprising that an increase in ligand (CRF) expression is associated with an increase in the expression of its cognate receptor CRFR1 rather than downregulation, but again this observation agrees very well with the animal experimental data. Injection of CRF in the rodent PVN increased CRFR1 expression, and the majority of the CRF-containing neurons in the PVN express this receptor. 47 There are also CRF synapses on CRF neurons present in the rat PVN. 48 In our study, the increase of CRF was accompanied by an increase of CRFR1 expression in the PVN. This suggests a Abbreviations: AR, androgen receptor; AVP, vasopressin; AVPR1A, AVP receptor 1a; CRF, corticotropin-releasing factor; CRFR, CRF receptors; CREB, cAMP-response element-binding protein; ESR, estrogen receptor; GR, glucocorticoid receptor; HSP, heat shock protein; IL1b, interleukin 1-b; MR, mineralocorticoid receptor; OXT, oxytocin; PVN, paraventricular nucleus; SON, supraoptic nucleus; TNFa, tumor necrosis factor-a. a P < 0.05, significant differences in the PVN and SON of the depressed patients. b P < 0.05, significant differences in the PVN and SON of the controls.
potential autocrine or neuroendocrine effect of CRF on CRF cells. CRF seems to enhance its own response to stress by increasing amount of CRFR1 in the CRF neural circuits within the PVN by an ultra short positive feedback loop as part of the functional adaptation of the HPA axis in response to stress. Indeed, a CRFR1 polymorphism is associated with an increased risk to present a seasonal pattern and an early onset of the first depressive episode, 49 indicating a possible causal role of this receptor in the pathogenesis of some aspects of depression. Moreover, CRFR1 seems to be involved in the antidepressant response to selective serotonin reuptake blocker.
11 CRFR2, which opposes the actions of CRFR1 22 and mediates an anxiolytic effect, 50 showed nonsignificant change, indicating an imbalance in the regulation of CRF in depression via the two CRF receptors. Our data support the hypothesis that increased CRF signaling via CRFR1 is an important mechanism in the pathogenesis of depression and that CRFR1 antagonists might be an effective novel class of antidepressant drugs.
21,51
CREB cAMP-response element-binding protein has a critical role as a transcription factor in the response to several signal transduction cascades. A genome-wide linkage survey suggested that pathways converging on CREB may also affect the development of MD. 52 There are cAMP-response elements located in the CRF gene promoter and binding of CREB stimulates CRF gene expression. 27 In vitro, glucocorticoids inhibit the CRF promoter through cAMP-dependent activity. 53 However, in our study, a change in CREB mRNA to accompany the increase of CRF mRNA expression in the PVN in depression was not found, so that our data do not provide support for a central role of CREB in the PVN in mood disorders. Alternatively, CRF gene regulation by CREB might not be attributed to different expression levels of CREB mRNA but to protein levels of phosphorylated CREB, which has been studied both in vitro and in vivo.
27,54
GR and MR imbalance
The glucocorticoid feedback on the HPA axis is mediated by two types of receptors, GR and MR that have a different localization in the brain. 16 In depression, a downregulation of these receptors, secondary to the persistent hypercortisolism was presumed. However, Young et al. 17 found with endocrine assays an indication that, despite the high basal cortisol levels in patients with MD, an increased functional activity of the MR system was present. We observed an increased expression of MR, whereas GRa was not altered and the GRb, as an inhibitory modulator of GRa, was undetectable. A very low GRb expression was also reported in the human hippocampus. 55 Our observations confirm, but now by direct measurements in the PVN, the findings of Young et al. 17 of increased MR and support the GR/MR imbalance hypothesis for depression as formulated by De Kloet et al. 16 The proportion of hetero-and homodimers of the MR and GR receptors influences the efficacy of gene transcription. 20 Our finding of an imbalance of MR/GR ratio in the PVN of depressed patients may, therefore, contribute to the change in transcription rate of CRF.
MR and GR in the hippocampus mediate in a coordinate manner the steroid control of HPA activity via GABAergic neurons. 56, 57 A balance between GR and MR is thought to be important for homeostasis and an imbalance through an excess of MR or GR was proposed to enhance vulnerability to depression. 16 MR has been found to colocalize with GR in the parvocellular neurons in rat PVN. 58 Fornix transaction or adrenalectomy induced a significant increase in MR mRNA signal in the parvocellular region together with an increase in CRF mRNA in the PVN. 59 The increased MR we found in the PVN thus agrees with the other measures of HPA-axis activation. Changes in corticosteroid receptor in depression seem to differ per brain region. 60 Decreased GR mRNA levels have been found in depression in various neocortical and hippocampal areas, while diminished MR levels were found in the prefrontal cortex, 61 which may contribute to the proposed imbalance between GR and MR in depression.
HSP
The assembly of various co-chaperone proteins, such as HSP70 and 90, to the GR-chaperone complex, directs the GR to adopt a glucocorticoid-binding conformation. Glucocorticoid resistance is frequently observed in depressed patients and is thought to be associated with alterations in HSP70 and 90. 33 In addition, some studies show that alterations in HSP70 or 90 are accompanied by mood disorders. 62, 63 However, we did not find different HSP70 or 90 expressions in the PVN in depressed patients and the data therefore do not support a central role for these HSP molecules in depression.
Sex hormones receptor imbalance
Fluctuations in sex hormone levels are a risk factor for depression. 1 In addition, polymorphisms in the genes for the sex hormone receptors AR and ESR1/2 were recently found to be risk factors for this disorder. 64 Sex hormones can affect the HPA axis in a direct way via ESRs and ARs that are expressed by CRF neurons. 28, 29 There are five perfect half-palindromic estrogenresponsive elements in the human CRF-promoter region, which may confer direct estrogenic stimulation on CRF gene expression. 28, 65 Differential effects have been described in vitro on gene expression by the two receptor subtypes ESR1 and 2.
66 ESR1 mRNA expression dominates in the human hypothalamus while ESR2 mRNA and protein were lower in this brain area. 28, 67 In contrast to estrogens, androgens may inhibit CRF gene expression via AR expressed by CRF neurons, acting by androgen-responsive elements in the CRF-promoter region. 29, 68 In the present study, we found a differential change in sex hormone receptors. The expression of ESR1 mRNA was upregu-lated in depressed subjects, whereas AR was downregulated compared with the controls. Both changes go together with increased CRF expression. Moreover, there was only a trend for an increase of ESR2 expression, while activation of this receptor subtype reduces anxiety. 69 The two ESR subtypes correlated positively both in depressed patients and controls (Figure 3a) , while a correlation between ESR and AR was only found in the PVN of depressed patients as shown in Figure 3b . Our data show an imbalance in the changes of the three sex hormone receptors that will contribute to the increased activity of the CRF neurons and thus to the signs and symptoms of depression.
Cytokines
Cytokine levels may be enhanced during depression and elicit depressive symptoms. 70, 71 CRF production is stimulated by proinflammatory cytokines such as IL1b, 72, 73 produced by glial cells and PVN neurons. 30 Also TNFa, a circulating state marker for depression may stimulate CRF production. 31, 74 In addition, TNFa is produced by astrocytes and ependymal cells. 32 In the present study, we did not find a change of TNFa or IL1b in mRNA levels in the PVN in depressed patients.
AVP
No significant difference of AVP mRNA expression was found between the SON or the PVN of controls and depressed patients, AVP mRNA expression was earlier found to be significantly increased in both the SON and the PVN, but only in the melancholic subgroup of depressed patients. 24 In the present study, only one patient was diagnosed as having the melancholic type of depression (Table 1) , which fully explained why we did not find a significant change of AVP mRNA in our group of depressed subjects.
The receptor AVPR1A was reported to be present in the rat PVN and to control hormone release. 75, 76 In animal experiments, AVPR1A immunoreactive cells in the PVN increased after mineralocorticoid administration 77 and an AVPR1A antagonist resulted in a decrease in anxiety/depression-related behavior. 25 The increased AVPR1A mRNA found in the PVN of depressed patients may therefore be directly related with the symptoms of depression.
Several limitations of the present study should be mentioned. The groups are relatively limited in size. However, for qPCR, frozen brain material is needed from clinically well-documented depressed patients and well-matched control material with a relatively short post-mortem time and good quality RNA, which is extremely difficult to obtain.
A second point is that the five MD subjects and the two BD patients may be seen as pathophysiologically non-identical entities. For instance, image studies showed that the hippocampal volume is reduced in MD, while BD patients did not show a reduction of hippocampal volume. 78 Indeed, for each depression subtype-and even probably for each MD patientthere are different genetic and epigenetic factors involved in the pathogenesis of depression. However, previous studies have shown that both, MD and BD, are accompanied by an activation of the final common pathway, the HPA axis. Both types of depression exhibit similar activation of the CRF-and ESR1-expressing neurons in the hypothalamic PVN, 4, 5, 28 both go together with a decreased activity in the biological clock. 79 Apparently, whatever the individual risk factors and pathogenetic mechanisms for MD and BD are, they ultimately seem to lead to similar activity changes on the level of the hypothalamus.
At a third point, it should be noted that the increased activity of the PVN CRF neurons in the patients with mood disorders is unlikely to be the result of the administration of antidepressants, since it has been found that they may attenuate rather than enhance the activity of CRF neurons. [80] [81] [82] [83] Thus, if antidepressants interfered with our measurements, this would have led to an underestimation of the observed difference between controls and patients with mood disorders with regard to the activation of their CRF-expressing neurons in the PVN. Furthermore, antidepressants did not influence AVP mRNA or OXT mRNA levels in PVN and SON in an animal experimental study. 84 On the effect on the expression of the other genes studied (MR, ESR, AR and CRFR), there is, however, insufficient information.
In conclusion, in the present study, we combined laser microdissection and real-time PCR, which enables detection of differences in gene expression levels in specific areas of the human hypothalamus. A combination of in situ hybridization and immunocytochemistry would be a next step to determine in what cell type in the PVN the expression of the different genes is localized. Our study contributes new data to the question how the activity of the HPA axis may be modulated by a number of factors in depression. The finding of multiple receptor imbalances in the PVN indicates new targets for future work, a study of possible cross talk between these receptors systems in the MD being one of them. The significant change in the expression of five genes that all indicate a stimulation of the HPA-axis activity may also offer new avenues for therapeutic strategies, such as testing combinations of different receptor agonists and antagonists.
